Nandor Gabor Than

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2100751/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Placental abruption as a trigger of DIC in women with HELLP syndrome: a population-based study. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 3259-3269.	0.7	10
2	Prediction of preeclampsia throughout gestation with maternal characteristics and biophysical and biochemical markers: a longitudinal study. American Journal of Obstetrics and Gynecology, 2022, 226, 126.e1-126.e22.	0.7	18
3	Early pathways, biomarkers, and four distinct molecular subclasses of preeclampsia: The intersection of clinical, pathological, and high-dimensional biology studies. Placenta, 2022, 125, 10-19.	0.7	19
4	Proteoglycans: Systems-Level Insight into Their Expression in Healthy and Diseased Placentas. International Journal of Molecular Sciences, 2022, 23, 5798.	1.8	8
5	Maternal whole blood mRNA signatures identify women at risk of early preeclampsia: a longitudinal study. Journal of Maternal-Fetal and Neonatal Medicine, 2021, 34, 3463-3474.	0.7	36
6	Epigenetic Dysregulation of Trophoblastic Gene Expression in Gestational Trophoblastic Disease. Biomedicines, 2021, 9, 1935.	1.4	7
7	Proteomic identification of Placental Protein 1 (PP1), PP8, and PP22 and characterization of their placental expression in healthy pregnancies and in preeclampsia. Placenta, 2020, 99, 197-207.	0.7	3
8	Pivotal role of the transcriptional co-activator YAP in trophoblast stemness of the developing human placenta. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 13562-13570.	3.3	95
9	Placenta-Specific Genes, Their Regulation During Villous Trophoblast Differentiation and Dysregulation in Preterm Preeclampsia. International Journal of Molecular Sciences, 2020, 21, 628.	1.8	30
10	Placental Galectins Are Key Players in Regulating the Maternal Adaptive Immune Response. Frontiers in Immunology, 2019, 10, 1240.	2.2	51
11	Dysregulation of Placental Functions and Immune Pathways in Complete Hydatidiform Moles. International Journal of Molecular Sciences, 2019, 20, 4999.	1.8	13
12	Increased placental expression of Placental Protein 5 (PP5) / Tissue Factor Pathway Inhibitor-2 (TFPI-2) in women with preeclampsia and HELLP syndrome: Relevance to impaired trophoblast invasion?. Placenta, 2019, 76, 30-39.	0.7	18
13	The prediction of early preeclampsia: Results from a longitudinal proteomics study. PLoS ONE, 2019, 14, e0217273.	1.1	81
14	Screening for preeclampsia in the first trimester of pregnancy in routine clinical practice in Hungary. Journal of Biotechnology, 2019, 300, 11-19.	1.9	4
15	Feto-Maternal Microchimerism: The Pre-eclampsia Conundrum. Frontiers in Immunology, 2019, 10, 659.	2.2	20
16	Sex hormone-binding globulin provides a novel entry pathway for estradiol and influences subsequent signaling in lymphocytes via membrane receptor. Scientific Reports, 2019, 9, 4.	1.6	29
17	Proteomic identification of membrane-associated placental protein 4 (MP4) as perlecan and characterization of its placental expression in normal and pathologic pregnancies. PeerJ, 2019, 7, e6982.	0.9	6
18	Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia. Frontiers in Immunology, 2018, 9, 1661.	2.2	146

Nandor Gabor Than

#	Article	IF	CITATIONS
19	Ethical issues in genetic counseling. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2017, 43, 32-49.	1.4	13
20	Cerebral Palsy—Trends in Epidemiology and Recent Development in Prenatal Mechanisms of Disease, Treatment, and Prevention. Frontiers in Pediatrics, 2017, 5, 21.	0.9	198
21	A longitudinal study of placental perfusion using dynamic contrast enhanced magnetic resonance imaging in murine pregnancy. Placenta, 2016, 43, 90-97.	0.7	16
22	Full-Length Human Placental sFlt-1-e15a Isoform Induces Distinct Maternal Phenotypes of Preeclampsia in Mice. PLoS ONE, 2015, 10, e0119547.	1.1	50
23	Activation of Villous Trophoblastic p38 and ERK1/2 Signaling Pathways in Preterm Preeclampsia and HELLP Syndrome. Pathology and Oncology Research, 2015, 21, 659-668.	0.9	36
24	Galectins: Double-edged Swords in the Cross-roads of Pregnancy Complications and Female Reproductive Tract Inflammation and Neoplasia. Journal of Pathology and Translational Medicine, 2015, 49, 181-208.	0.4	54
25	Placental Protein 13 (PP13) ââ,¬â€œ A Placental Immunoregulatory Galectin Protecting Pregnancy. Frontiers in Immunology, 2014, 5, 348.	2.2	90
26	The peripheral whole-blood transcriptome of acute pyelonephritis in human pregnancy ^a . Journal of Perinatal Medicine, 2014, 42, 31-53.	0.6	20
27	Evaluation of Utero-placental and Fetal Hemodynamic Parameters Throughout Gestation in Pregnant Mice Using High-Frequency Ultrasound. Ultrasound in Medicine and Biology, 2014, 40, 351-360.	0.7	19
28	DIC Score in Pregnant Women – A Population Based Modification of the International Society on Thrombosis and Hemostasis Score. PLoS ONE, 2014, 9, e93240.	1.1	88
29	In Vivo Experiments Reveal the Good, the Bad and the Ugly Faces of sFlt-1 in Pregnancy. PLoS ONE, 2014, 9, e110867.	1.1	40
30	Changes of placental syndecan-1 expression in preeclampsia and HELLP syndrome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 445-458.	1.4	42
31	Analysis and correction of crosstalk effects in pathway analysis. Genome Research, 2013, 23, 1885-1893.	2.4	123
32	Methodological approach from the Best Overall Team in the sbv IMPROVER Diagnostic Signature Challenge. Systems Biomedicine (Austin, Tex), 2013, 1, 217-227.	0.7	9
33	Galectins: guardians of eutherian pregnancy at the maternal–fetal interface. Trends in Endocrinology and Metabolism, 2012, 23, 23-31.	3.1	82
34	Placental protein 13 (PP13/galectin-13) undergoes lipid raft-associated subcellular redistribution in the syncytiotrophoblast in preterm preeclampsia and HELLP syndrome. American Journal of Obstetrics and Gynecology, 2011, 205, 156.e1-156.e14.	0.7	50
35	PP13, Maternal ABO Blood Groups and the Risk Assessment of Pregnancy Complications. PLoS ONE, 2011, 6, e21564.	1.1	45
36	A primate subfamily of galectins expressed at the maternal–fetal interface that promote immune cell death. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9731-9736.	3.3	200

#	Article	IF	CITATIONS
37	Placental protein 13 (galectin-13) has decreased placental expression but increased shedding and maternal serum concentrations in patients presenting with preterm pre-eclampsia and HELLP syndrome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 453, 387-400.	1.4	113
38	ORIGINAL ARTICLE: A Role for Mannoseâ€Binding Lectin, a Component of the Innate Immune System in Preâ€Eclampsia. American Journal of Reproductive Immunology, 2008, 60, 333-345.	1.2	43
39	ORICINAL ARTICLE: Chorioamnionitis and Increased Galectinâ€l Expression in PPROM – An Antiâ€Inflammatory Response in the Fetal Membranes?. American Journal of Reproductive Immunology, 2008, 60, 298-311.	1.2	43
40	The anti-inflammatory limb of the immune response in preterm labor, intra-amniotic infection/inflammation, and spontaneous parturition at term: A role for interleukin-10. Journal of Maternal-Fetal and Neonatal Medicine, 2008, 21, 529-547.	0.7	119
41	Severe preeclampsia is characterized by increased placental expression of galectin-1. Journal of Maternal-Fetal and Neonatal Medicine, 2008, 21, 429-442.	0.7	65
42	The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. Journal of Maternal-Fetal and Neonatal Medicine, 2008, 21, 279-287.	0.7	264
43	Emergence of hormonal and redox regulation of galectin-1 in placental mammals: Implication in maternal–fetal immune tolerance. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 15819-15824.	3.3	86
44	Normal and abnormal transformation of the spiral arteries during pregnancy. Journal of Perinatal Medicine, 2006, 34, 447-58.	0.6	148